This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Subscribe To Our Newsletter & Stay Updated
